[Retracted] Efficacy Evaluation of Inflammatory Mediators in the Treatment of Multiple Myeloma with Daratumumab

Table 1

Disease characteristics of enrolled patients.

	Experimental group	Control group
Gender	2 : 5	7 : 7
Age	Age 52–81 (average 65)	Age 51–82 (average 68)
DS staging ratio (I : II : III)	0 : 0 : 100%	0 : 0 : 100%
ISS staging ratio (I : II : III)	1 : 4:2	1 : 5 : 8
R-ISS staging ratio (I : II : III)	0 : 1:6	1 : 6 : 7
SMART staging (standard risk: high risk)	1 : 6	10 : 4